Revolutionizing the treatment of immunological diseases
We are advancing two B10 cell-based technologies that can either enhance or inhibit immune responses. We believe these have the potential to profoundly advance treatments for inflammation, autoimmunity, solid tumors and infection.
Our first-in-class regulatory B10 cell-directed therapies take a unique approach and distinguish us from others working in the immunotherapy area. We have one of the leading pipelines in B cell therapy.
The science behind our technology is well-vetted and supported by numerous peer-reviewed publications.